The agency is proposing drugmakers use shorter nonrodent studies and other sources of evidence when developing monoclonal antibodies for non-cancer settings.

The study will test the therapy in lung, colorectal, and head and neck cancer patients with B7H3 and PTK7 mutations.

The company is evaluating EN-374 in patients with X-linked chronic granulomatous disease as part of a Phase I/II trial.

Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk will collaborate with PRECISE to analyze whole-genome and other data on 100,000 Singaporeans.

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

The partners will also leverage AI tools and proprietary evaluation models to home in on targetable shared cancer antigens and develop vaccines against them.

Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.

NEW YORK – Fifteen drugs will be offered at a lower cost under Medicare Part D beginning in 2027 after the latest round of drug price negotiations between pharma companies and the Centers for Medicare ...

The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel ...

The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.

Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...